

BP-50620

Epcoritamab Biosimilar – Anti-CD20/CD3 Bispecific Antibody

Epcoritamab (sold under the brand names Epkinly in the U.S. and Japan, and Tepkinly in the EU) is a bispecific T-cell engager (BiTE) immunotherapy designed to bind to the CD3 protein on healthy T-cells and the CD20 protein on malignant B-cells. It is approved for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). By physically bridging the two together, it directs the patient's own immune system to target and destroy the lymphoma cells.

Product Details	
Species Reactivity	Human
Source	Mammalian Cells
Isotype	Ig(G1-kappa_G1-lambda2)
Class	Anti-Human Bispecific antibodies
Type	Recombinant Humanized
Clone	NA
Target	Anti-human CD20/CD3
Purity	>99%
Molecular Weight	146.28 kDa
CAS Number	2134641-34-0
Formulation	NA
Storage conditions	Store at -80°C for 2 years. Aliquots should be stored at the same temperature after first use to avoid multiple freeze-thaws Addition of 20 to 40 % glycerol may improve cryoprotection. Purified antibodies should ideally be stored as 0.5 to 2.0 mg/ml stock solutions. Aliquot the product according to your needs to avoid freeze/thaw cycles.